Annual CFF
$311.72 M
+$130.39 M+71.90%
December 31, 2022
Summary
- As of March 10, 2025, SRNE annual cash flow from financing activities is $311.72 million, with the most recent change of +$130.39 million (+71.90%) on December 31, 2022.
- During the last 3 years, SRNE annual CFF has risen by +$232.83 million (+295.15%).
- SRNE annual CFF is now -4.38% below its all-time high of $326.00 million, reached on December 31, 2018.
Performance
SRNE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$88.81 M
+$27.62 M+45.13%
June 30, 2023
Summary
- As of March 10, 2025, SRNE quarterly cash flow from financing activities is $88.81 million, with the most recent change of +$27.62 million (+45.13%) on June 30, 2023.
- Over the past year, SRNE quarterly CFF has increased by +$27.62 million (+45.13%).
- SRNE quarterly CFF is now -48.77% below its all-time high of $173.37 million, reached on March 31, 2022.
Performance
SRNE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$246.59 M
+$47.04 M+23.57%
June 30, 2023
Summary
- As of March 10, 2025, SRNE TTM cash flow from financing activities is $246.59 million, with the most recent change of +$47.04 million (+23.57%) on June 30, 2023.
- Over the past year, SRNE TTM CFF has increased by +$47.04 million (+23.57%).
- SRNE TTM CFF is now -31.02% below its all-time high of $357.50 million, reached on September 30, 2022.
Performance
SRNE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SRNE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +71.9% | +45.1% | +23.6% |
| 3 y3 years | +295.1% | +45.1% | +23.6% |
| 5 y5 years | +480.8% | +45.1% | +23.6% |
SRNE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +71.9% | -48.8% | +254.1% | -31.0% | +36.0% |
| 5 y | 5-year | at high | +295.1% | -48.8% | +867.2% | -31.0% | +212.6% |
| alltime | all time | -4.4% | +9413.4% | -48.8% | +495.0% | -31.0% | +7467.4% |
Sorrento Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | $88.81 M(+45.1%) | $246.59 M(+23.6%) |
| Mar 2023 | - | $61.20 M(+144.0%) | $199.54 M(-36.0%) |
| Dec 2022 | $311.72 M(+71.9%) | $25.08 M(-64.9%) | $311.72 M(-12.8%) |
| Sep 2022 | - | $71.50 M(+71.2%) | $357.50 M(+9.6%) |
| Jun 2022 | - | $41.77 M(-75.9%) | $326.06 M(+2.1%) |
| Mar 2022 | - | $173.37 M(+144.7%) | $319.34 M(+76.1%) |
| Dec 2021 | $181.33 M(+4.1%) | $70.86 M(+76.9%) | $181.33 M(+83.4%) |
| Sep 2021 | - | $40.06 M(+14.3%) | $98.90 M(-44.0%) |
| Jun 2021 | - | $35.06 M(-0.8%) | $176.69 M(-4.4%) |
| Mar 2021 | - | $35.36 M(-405.4%) | $184.87 M(+6.1%) |
| Dec 2020 | $174.24 M(+120.9%) | -$11.58 M(-109.8%) | $174.24 M(-22.1%) |
| Sep 2020 | - | $117.85 M(+172.6%) | $223.72 M(+74.2%) |
| Jun 2020 | - | $43.24 M(+74.9%) | $128.44 M(+22.7%) |
| Mar 2020 | - | $24.72 M(-34.8%) | $104.70 M(+32.7%) |
| Dec 2019 | $78.89 M(-75.8%) | $37.91 M(+68.0%) | $78.89 M(-36.5%) |
| Sep 2019 | - | $22.57 M(+15.7%) | $124.27 M(-53.8%) |
| Jun 2019 | - | $19.50 M(-1877.8%) | $269.00 M(-9.3%) |
| Mar 2019 | - | -$1.10 M(-101.3%) | $296.67 M(-9.0%) |
| Dec 2018 | $326.00 M(+507.4%) | $83.30 M(-50.2%) | $326.00 M(+20.2%) |
| Sep 2018 | - | $167.30 M(+254.7%) | $271.22 M(+156.0%) |
| Jun 2018 | - | $47.17 M(+67.1%) | $105.96 M(+1.5%) |
| Mar 2018 | - | $28.23 M(-1.0%) | $104.39 M(+94.5%) |
| Dec 2017 | $53.67 M(-59.3%) | $28.51 M(+1293.6%) | $53.67 M(-23.6%) |
| Sep 2017 | - | $2.05 M(-95.5%) | $70.29 M(+15.0%) |
| Jun 2017 | - | $45.60 M(-302.8%) | $61.12 M(-42.7%) |
| Mar 2017 | - | -$22.48 M(-149.8%) | $106.70 M(-19.0%) |
| Dec 2016 | $131.74 M(-4036.1%) | $45.13 M(-733.5%) | $131.74 M(+55.9%) |
| Sep 2016 | - | -$7.12 M(-107.8%) | $84.50 M(-7.2%) |
| Jun 2016 | - | $91.18 M(+3465.7%) | $91.04 M(<-9900.0%) |
| Mar 2016 | - | $2.56 M(-221.2%) | -$79.00 K(-97.6%) |
| Dec 2015 | -$3.35 M(-104.2%) | -$2.11 M(+260.1%) | -$3.35 M(-107.6%) |
| Sep 2015 | - | -$586.00 K(-1076.7%) | $44.21 M(-1.2%) |
| Jun 2015 | - | $60.00 K(-108.4%) | $44.74 M(-37.3%) |
| Mar 2015 | - | -$711.00 K(-101.6%) | $71.38 M(-10.3%) |
| Dec 2014 | $79.59 M | $45.45 M(<-9900.0%) | $79.59 M(+20.0%) |
| Sep 2014 | - | -$55.00 K(-100.2%) | $66.35 M(-6.0%) |
| Jun 2014 | - | $26.70 M(+256.0%) | $70.58 M(+61.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $7.50 M(-76.7%) | $43.83 M(+0.6%) |
| Dec 2013 | $43.57 M(+629.8%) | $32.21 M(+671.8%) | $43.57 M(+282.4%) |
| Sep 2013 | - | $4.17 M(-8616.3%) | $11.39 M(+57.8%) |
| Jun 2013 | - | -$49.00 K(-100.7%) | $7.22 M(-45.3%) |
| Mar 2013 | - | $7.24 M(>+9900.0%) | $13.21 M(+121.2%) |
| Dec 2012 | $5.97 M(+200.9%) | $31.80 K(>+9900.0%) | $5.97 M(-24.6%) |
| Sep 2012 | - | $0.00(-100.0%) | $7.91 M(0.0%) |
| Jun 2012 | - | $5.94 M(>+9900.0%) | $7.91 M(+298.9%) |
| Mar 2012 | - | $0.00(-100.0%) | $1.98 M(0.0%) |
| Dec 2011 | $1.98 M(-42.3%) | $1.98 M(>+9900.0%) | $1.98 M(-42.5%) |
| Sep 2011 | - | $0.00(-100.0%) | $3.45 M(0.0%) |
| Jun 2011 | - | $7900.00(>+9900.0%) | $3.45 M(+0.2%) |
| Mar 2011 | - | $0.00(-100.0%) | $3.44 M(0.0%) |
| Dec 2010 | $3.44 M(-16.2%) | $3.44 M(>+9900.0%) | $3.44 M(>+9900.0%) |
| Sep 2010 | - | $0.00(0.0%) | $1600.00(-99.9%) |
| Jun 2010 | - | $0.00(0.0%) | $1.83 M(-55.4%) |
| Mar 2010 | - | $0.00(-100.0%) | $4.11 M(0.0%) |
| Dec 2009 | $4.11 M(>+9900.0%) | $1600.00(-99.9%) | $4.11 M(+15.9%) |
| Sep 2009 | - | $1.83 M(-19.6%) | $3.54 M(+55.7%) |
| Jun 2009 | - | $2.27 M(-504.3%) | $2.27 M(>+9900.0%) |
| Dec 2008 | $0.00(-100.0%) | -$562.50 K(-200.0%) | $0.00(-100.0%) |
| Sep 2008 | - | $562.50 K(>+9900.0%) | $562.50 K(>+9900.0%) |
| Jun 2008 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2008 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2007 | $690.00 K(>+9900.0%) | $0.00(0.0%) | $690.00 K(0.0%) |
| Sep 2007 | - | $0.00(0.0%) | $690.00 K(0.0%) |
| Jun 2007 | - | $0.00(-100.0%) | $690.00 K(0.0%) |
| Mar 2007 | - | $690.00 K(-7363.2%) | $690.00 K(-7363.2%) |
| Dec 2006 | $0.00(-100.0%) | - | - |
| Dec 2005 | -$9500.00(<-9900.0%) | -$9500.00(<-9900.0%) | -$9500.00(<-9900.0%) |
| Sep 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2004 | $0.00(0.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2004 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2004 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2004 | - | $0.00 | $0.00 |
| Dec 2003 | $0.00 | - | - |
FAQ
- What is Sorrento Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Sorrento Therapeutics?
- What is Sorrento Therapeutics annual CFF year-on-year change?
- What is Sorrento Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Sorrento Therapeutics?
- What is Sorrento Therapeutics quarterly CFF year-on-year change?
- What is Sorrento Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Sorrento Therapeutics?
- What is Sorrento Therapeutics TTM CFF year-on-year change?
What is Sorrento Therapeutics annual cash flow from financing activities?
The current annual CFF of SRNE is $311.72 M
What is the all time high annual CFF for Sorrento Therapeutics?
Sorrento Therapeutics all-time high annual cash flow from financing activities is $326.00 M
What is Sorrento Therapeutics annual CFF year-on-year change?
Over the past year, SRNE annual cash flow from financing activities has changed by +$130.39 M (+71.90%)
What is Sorrento Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SRNE is $88.81 M
What is the all time high quarterly CFF for Sorrento Therapeutics?
Sorrento Therapeutics all-time high quarterly cash flow from financing activities is $173.37 M
What is Sorrento Therapeutics quarterly CFF year-on-year change?
Over the past year, SRNE quarterly cash flow from financing activities has changed by +$27.62 M (+45.13%)
What is Sorrento Therapeutics TTM cash flow from financing activities?
The current TTM CFF of SRNE is $246.59 M
What is the all time high TTM CFF for Sorrento Therapeutics?
Sorrento Therapeutics all-time high TTM cash flow from financing activities is $357.50 M
What is Sorrento Therapeutics TTM CFF year-on-year change?
Over the past year, SRNE TTM cash flow from financing activities has changed by +$47.04 M (+23.57%)